JP2018527336A - ３−インドール置換誘導体、医薬組成物、および使用方法 - Google Patents
３−インドール置換誘導体、医薬組成物、および使用方法 Download PDFInfo
- Publication number
- JP2018527336A JP2018527336A JP2018506432A JP2018506432A JP2018527336A JP 2018527336 A JP2018527336 A JP 2018527336A JP 2018506432 A JP2018506432 A JP 2018506432A JP 2018506432 A JP2018506432 A JP 2018506432A JP 2018527336 A JP2018527336 A JP 2018527336A
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- indol
- phenyl
- sulfonyl
- benzenesulfonamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *c1c[n](*)c2cc(*)c(*)cc12 Chemical compound *c1c[n](*)c2cc(*)c(*)cc12 0.000 description 4
- ANYUHMHSOONIKF-UHFFFAOYSA-N CCCN(CCC=N)C(NCCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O Chemical compound CCCN(CCC=N)C(NCCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O ANYUHMHSOONIKF-UHFFFAOYSA-N 0.000 description 1
- RSZNQULXVIJVJA-UHFFFAOYSA-N CN(C(CN(C1)S(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=O)C1=O Chemical compound CN(C(CN(C1)S(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=O)C1=O RSZNQULXVIJVJA-UHFFFAOYSA-N 0.000 description 1
- UKYPNXUVLRQSOI-UHFFFAOYSA-N CN(C)C(CCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O Chemical compound CN(C)C(CCNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)=O UKYPNXUVLRQSOI-UHFFFAOYSA-N 0.000 description 1
- AQGYUKXHLHYMHX-UHFFFAOYSA-N CNC(c(cc(cc1)-c2c[nH]c3cc(F)ccc23)c1S(N1CCNCC1)(=O)=O)=O Chemical compound CNC(c(cc(cc1)-c2c[nH]c3cc(F)ccc23)c1S(N1CCNCC1)(=O)=O)=O AQGYUKXHLHYMHX-UHFFFAOYSA-N 0.000 description 1
- KGYVMYHZZQRVHB-UHFFFAOYSA-N CS(c(c(CN)c1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O Chemical compound CS(c(c(CN)c1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O KGYVMYHZZQRVHB-UHFFFAOYSA-N 0.000 description 1
- VDXFXOOVWIKTGE-OKILXGFUSA-N C[C@H](C1)N[C@@H](C)CN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O Chemical compound C[C@H](C1)N[C@@H](C)CN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O VDXFXOOVWIKTGE-OKILXGFUSA-N 0.000 description 1
- HAVXYUYSVFFDAF-LLVKDONJSA-N C[C@H](CNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)O Chemical compound C[C@H](CNS(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O)O HAVXYUYSVFFDAF-LLVKDONJSA-N 0.000 description 1
- OJOODCWBFOKGNX-UHFFFAOYSA-N Cc([nH]c1c2ccc(F)c1)c2-c(cc1)ccc1S(NCCc1ncc[nH]1)(=O)=O Chemical compound Cc([nH]c1c2ccc(F)c1)c2-c(cc1)ccc1S(NCCc1ncc[nH]1)(=O)=O OJOODCWBFOKGNX-UHFFFAOYSA-N 0.000 description 1
- JZRZPFQQIOFCGL-UHFFFAOYSA-N Cc1nnc(CNC/[O]=S/c(cc2)ccc2C(c(c(NC)c2)ccc2F)=C)[o]1 Chemical compound Cc1nnc(CNC/[O]=S/c(cc2)ccc2C(c(c(NC)c2)ccc2F)=C)[o]1 JZRZPFQQIOFCGL-UHFFFAOYSA-N 0.000 description 1
- LXIUPELUVIEOAP-UHFFFAOYSA-N NC([n]1c(cc(cc2)F)c2c(-c(cc2)ccc2S(N2CCNCC2)(=O)=O)c1)=O Chemical compound NC([n]1c(cc(cc2)F)c2c(-c(cc2)ccc2S(N2CCNCC2)(=O)=O)c1)=O LXIUPELUVIEOAP-UHFFFAOYSA-N 0.000 description 1
- MCUULSPCLNTZND-UHFFFAOYSA-N NCCN(CCN(C1)S(c(cc2)ccc2-c2c[nH]c3c2ccc(F)c3)(=O)=O)C1=O Chemical compound NCCN(CCN(C1)S(c(cc2)ccc2-c2c[nH]c3c2ccc(F)c3)(=O)=O)C1=O MCUULSPCLNTZND-UHFFFAOYSA-N 0.000 description 1
- QLGVTEJXKWYKRA-UHFFFAOYSA-N O=C1OC(CCNS(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=NN1 Chemical compound O=C1OC(CCNS(c(cc2)ccc2-c2c[nH]c3cc(F)ccc23)(=O)=O)=NN1 QLGVTEJXKWYKRA-UHFFFAOYSA-N 0.000 description 1
- VFQNXFRQJMGQJU-UHFFFAOYSA-N O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N1CCOCC1)=O Chemical compound O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N1CCOCC1)=O VFQNXFRQJMGQJU-UHFFFAOYSA-N 0.000 description 1
- CZKCKAFNBOJQNQ-CQSZACIVSA-N O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N[C@H]1COCC1)=O Chemical compound O=S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(N[C@H]1COCC1)=O CZKCKAFNBOJQNQ-CQSZACIVSA-N 0.000 description 1
- ZBVVEAXIBGDORR-UHFFFAOYSA-N OC(CC1)NCCN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O Chemical compound OC(CC1)NCCN1S(c(cc1)ccc1-c1c[nH]c2cc(F)ccc12)(=O)=O ZBVVEAXIBGDORR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562203032P | 2015-08-10 | 2015-08-10 | |
| US62/203,032 | 2015-08-10 | ||
| US201662309530P | 2016-03-17 | 2016-03-17 | |
| US62/309,530 | 2016-03-17 | ||
| PCT/IB2016/054701 WO2017025868A1 (en) | 2015-08-10 | 2016-08-04 | 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018527336A true JP2018527336A (ja) | 2018-09-20 |
| JP2018527336A5 JP2018527336A5 (enExample) | 2019-09-05 |
Family
ID=56801656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506432A Ceased JP2018527336A (ja) | 2015-08-10 | 2016-08-04 | ３−インドール置換誘導体、医薬組成物、および使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10544095B2 (enExample) |
| EP (1) | EP3334733A1 (enExample) |
| JP (1) | JP2018527336A (enExample) |
| CA (1) | CA2994917A1 (enExample) |
| WO (1) | WO2017025868A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016147144A1 (en) * | 2015-03-17 | 2016-09-22 | Pfizer Inc. | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| KR101997241B1 (ko) | 2015-05-21 | 2019-07-09 | 하푼 테라퓨틱스, 인크. | 삼중특이성 결합 단백질 및 사용 방법 |
| JP2019516700A (ja) * | 2016-05-12 | 2019-06-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Ａｓｈ１ｌ阻害剤及びそれを用いた治療方法 |
| US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
| EP3269714A1 (en) * | 2016-07-13 | 2018-01-17 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
| GB201705263D0 (en) | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| AU2018265856B2 (en) | 2017-05-12 | 2023-04-27 | Harpoon Therapeutics, Inc. | Mesothelin binding proteins |
| CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
| CA3060989A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
| WO2019075359A1 (en) | 2017-10-13 | 2019-04-18 | Harpoon Therapeutics, Inc. | TRISPECIFIC PROTEINS AND METHODS OF USE |
| IL315737A (en) | 2017-10-13 | 2024-11-01 | Harpoon Therapeutics Inc | B-cell maturation antigen-binding proteins |
| CA3082077A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| CN108794376B (zh) * | 2018-04-28 | 2021-01-05 | 北京施安泰医药技术开发有限公司 | 甲酰胺类衍生物、其药物组合物、制备方法与用途 |
| US12195544B2 (en) | 2018-09-21 | 2025-01-14 | Harpoon Therapeutics, Inc. | EGFR binding proteins and methods of use |
| BR112021005769A2 (pt) | 2018-09-25 | 2021-07-06 | Harpoon Therapeutics Inc | proteínas de ligação a dll3 e métodos de uso |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| AU2021226012A1 (en) * | 2020-02-27 | 2022-09-22 | Board Of Regents, The University Of Texas System | Methods and compositions for treatment of APC-deficient cancer |
| CN111825678A (zh) * | 2020-06-05 | 2020-10-27 | 连庆泉 | 一种卡马替尼的制备方法 |
| CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| MX2024000674A (es) | 2021-07-13 | 2024-02-07 | BioNTech SE | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| CN119156403A (zh) | 2022-03-08 | 2024-12-17 | 阿伦蒂斯治疗股份公司 | 抗紧密连接蛋白-1抗体增加t细胞可用性的用途 |
| IL321098A (en) | 2022-12-14 | 2025-07-01 | Astellas Pharma Europe Bv | Combination therapy including bispecific binding agents that bind to CLDN18.2- and CD3- and immune checkpoint inhibitors |
| WO2025121445A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534665A (ja) * | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
| WO2015082499A2 (en) * | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| WO2018011227A1 (en) * | 2016-07-13 | 2018-01-18 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE509731C2 (sv) | 1996-05-14 | 1999-03-01 | Labwell Ab | Metod för palladium-katalyserade organiska reaktioner innefattande ett uppvärmningssteg utfört med mikrovågsenergi |
| JP2000095759A (ja) | 1998-07-21 | 2000-04-04 | Takeda Chem Ind Ltd | 三環性化合物、その製造法および剤 |
| US6265403B1 (en) | 1999-01-20 | 2001-07-24 | Merck & Co., Inc. | Angiogenesis inhibitors |
| BR0212613A (pt) | 2001-09-19 | 2004-08-31 | Pharmacia Corp | Compostos de indazol substituìdos para o tratamento de inflamação |
| DE60331219D1 (de) | 2002-03-28 | 2010-03-25 | Eisai R&D Man Co Ltd | Azaindole als hemmstoffe von c-jun n-terminalen kinasen |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| FR2845996A1 (fr) | 2002-10-16 | 2004-04-23 | Servier Lab | Nouveaux derives de[3,4-a:3,4-c]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN1794986B (zh) | 2003-03-27 | 2012-09-05 | 兰肯瑙医学研究所 | 治疗癌症的新药物 |
| FR2862647B1 (fr) | 2003-11-25 | 2008-07-04 | Aventis Pharma Sa | Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant |
| GB0328909D0 (en) | 2003-12-12 | 2004-01-14 | Syngenta Participations Ag | Chemical compounds |
| GB0415746D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| NZ560225A (en) | 2005-02-09 | 2010-10-29 | Arqule Inc | Maleimide derivatives, pharmaceutical compositions and methods for treatment of cancer |
| WO2007039580A1 (en) | 2005-10-05 | 2007-04-12 | Nycomed Gmbh | Imidazolyl-substituted benzophenone compounds |
| WO2007045622A1 (en) | 2005-10-18 | 2007-04-26 | Nycomed Gmbh | Oxazolo [4 , 5-b] pyridine compounds as nitric oxide synthase inhibitors |
| WO2007050963A1 (en) | 2005-10-27 | 2007-05-03 | Lankenau Institute For Medical Research | Novel ido inhibitors and methods of use thereof |
| CN101374808B (zh) | 2006-01-24 | 2011-05-25 | 伊莱利利公司 | 孕酮受体的吲哚磺酰胺调节剂 |
| US8008481B2 (en) | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| KR20080108517A (ko) | 2006-04-05 | 2008-12-15 | 노파르티스 아게 | 암을 치료하기 위한 치료제의 조합물 |
| GB0624308D0 (en) | 2006-12-05 | 2007-01-17 | Molmed Spa | Combination product |
| US8058272B2 (en) | 2006-12-07 | 2011-11-15 | Novartis Ag | Organic compounds |
| CA2677096A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | Kinase inhibitors |
| EP2137168B1 (en) | 2007-03-16 | 2016-09-14 | Lankenau Institute for Medical Research | Novel ido inhibitors and methods of use thereof |
| US7868001B2 (en) | 2007-11-02 | 2011-01-11 | Hutchison Medipharma Enterprises Limited | Cytokine inhibitors |
| JP2011508725A (ja) | 2007-11-30 | 2011-03-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | プロリルヒドロキシラーゼ阻害剤 |
| AU2009228765B2 (en) | 2008-03-24 | 2012-05-31 | Novartis Ag | Arylsulfonamide-based matrix metalloprotease inhibitors |
| US20110159017A1 (en) | 2008-04-11 | 2011-06-30 | Ludwig Institute For Cancer Research Ltd. | Trytophan catabolism in cancer treatment and diagnosis |
| DE102008052943A1 (de) | 2008-10-23 | 2010-04-29 | Merck Patent Gmbh | Azaindolderivate |
| WO2010096389A1 (en) | 2009-02-17 | 2010-08-26 | Vertex Pharmaceuticals Incorporated | Tetrahydrothiazolopyridine inhibitors of phosphatidylinositol 3-kinase |
| US8158625B2 (en) | 2009-05-27 | 2012-04-17 | Genentech, Inc. | Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use |
| CA2668905A1 (en) * | 2009-06-15 | 2010-12-15 | University Of Saskatchewan | Method for inhibiting brassinin oxidase |
| KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| AU2010298168B2 (en) | 2009-09-23 | 2015-11-19 | Medivation Technologies, Inc. | Pyrido(3,4-b)indoles and methods of use |
| BR112012006956A2 (pt) | 2009-10-12 | 2015-09-15 | Bayer Cropscience Ag | 1- (pirida-3-il) -pirazóisol e 1- (pirimida-5-il) - pirazóisol como pesticidas |
| CN102656141B (zh) | 2009-10-13 | 2016-04-06 | 利亘制药公司 | 模拟造血生长因子的小分子化合物及其用途 |
| CN103282034A (zh) | 2010-11-18 | 2013-09-04 | 利亘制药公司 | 造血生长因子模拟物的用途 |
| AU2012230890A1 (en) | 2011-03-22 | 2013-09-26 | Amgen Inc. | Azole compounds as Pim inhibitors |
| US9273029B2 (en) | 2011-05-23 | 2016-03-01 | Merck Patent Gmbh | Pyridine-and pyrazine derivatives |
| EP2744805A1 (en) | 2011-08-17 | 2014-06-25 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| US20160263087A1 (en) | 2013-11-08 | 2016-09-15 | Iteos Therapeutics | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| US9126984B2 (en) | 2013-11-08 | 2015-09-08 | Iteos Therapeutics | 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use |
| JP2017505346A (ja) * | 2014-02-12 | 2017-02-16 | アイティーオス セラペウティクス | 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法 |
| US20150266857A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| CA2942761A1 (en) | 2014-03-18 | 2015-09-24 | Iteos Therapeutics | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use |
| SG11201608708WA (en) | 2014-05-15 | 2016-11-29 | Iteos Therapeutics | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors |
-
2016
- 2016-08-04 CA CA2994917A patent/CA2994917A1/en not_active Abandoned
- 2016-08-04 JP JP2018506432A patent/JP2018527336A/ja not_active Ceased
- 2016-08-04 WO PCT/IB2016/054701 patent/WO2017025868A1/en not_active Ceased
- 2016-08-04 US US15/749,963 patent/US10544095B2/en active Active
- 2016-08-04 EP EP16757354.2A patent/EP3334733A1/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534665A (ja) * | 2007-07-25 | 2010-11-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルココルチコイドミメチックス、それらの製造方法、医薬組成物、及びこれらの使用 |
| WO2015082499A2 (en) * | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| WO2018011227A1 (en) * | 2016-07-13 | 2018-01-18 | Netherlands Translational Research Center B.V. | Inhibitors of tryptophan 2,3-dioxygenase |
Non-Patent Citations (1)
| Title |
|---|
| DATABASE REGISTRY, JPN7020001518, 16 December 2011 (2011-12-16), ISSN: 0004281223 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2994917A1 (en) | 2017-02-16 |
| WO2017025868A1 (en) | 2017-02-16 |
| EP3334733A1 (en) | 2018-06-20 |
| US10544095B2 (en) | 2020-01-28 |
| US20180222862A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10544095B2 (en) | 3-indol substituted derivatives, pharmaceutical compositions and methods for use | |
| JP6775516B2 (ja) | 新奇な３−インドール置換誘導体、医薬組成物、および使用方法 | |
| JP6104268B2 (ja) | パーキンソン病の処置のためのキナーゼｌｒｒｋ２モジュレーターとしての２−フェニルアミノピリミジン誘導体 | |
| CN103459369B (zh) | 胍化合物 | |
| CN115397821A (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| JP5713367B2 (ja) | Ｌｒｒｋ２モジュレーターとしてのアミノピリミジン誘導体 | |
| RU2587493C2 (ru) | Производные диаминопиримидина и способы их получения | |
| CN102229605B (zh) | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 | |
| CN112638373A (zh) | 细胞周期蛋白依赖性激酶抑制剂 | |
| US20160263087A1 (en) | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | |
| US20150328228A1 (en) | Novel 4-(indol-3-yl)-pyrazole derivatives, pharmaceutical compositions and methods for use | |
| JP2017507983A (ja) | 新規な３−インドール置換誘導体、医薬組成物、および使用方法 | |
| JP2017505346A (ja) | 新規な３−（インドール−３−イル）−ピリジン誘導体、医薬組成物、および使用方法 | |
| TWI647227B (zh) | ２－醯胺噻唑衍生物或其鹽 | |
| CN105189480A (zh) | 在治疗由IKKε和/或TBK-1机制介导的疾病中有用的嘧啶化合物 | |
| EP1730114A1 (en) | Benzazepine derivatives for the treatment of neurological and psychiatric disorders | |
| CN102112449A (zh) | 苯基或吡啶基取代的吲唑衍生物 | |
| PT1802307E (pt) | Derivados de pirrolidina como ligandos de receptores de histamina | |
| CN108349935B (zh) | 吡咯烷衍生物 | |
| JP2016535097A (ja) | ４−（インドール−３−イル）−ピラゾール誘導体、医薬組成物および使用のための方法 | |
| HK1207855A1 (en) | Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists | |
| CN115996910A (zh) | 芳基或杂芳基衍生物 | |
| HK1100823A1 (en) | 3-or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| HK1100823B (en) | 3-or 4-monosubstituted phenol and thiophenol derivatives useful as h3 ligands | |
| HK1191938B (en) | Indazolyl triazole derivatives as irak inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190723 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190723 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200528 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200909 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210323 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20210817 |